Table 1.

Registrational Trials in Nonselective Inhibitors for Advanced Thyroid Cancers

Drug	Target(s)	Trial	Patient population	Trial design	Primary outcome
RAIR-DTC
Sorafenib	VEGFR1–3, RET, RAF, PDGFRβ	DECISION (22)	417 Patients with progressive RAIR-DTC	Placebo-controlled phase III	Median PFS = 10.8 months (sorafenib) vs. 5.8 months (placebo)
Lenvatinib	VEGFR1–3, FGFR1–4, PDGFRα, RET, KIT	SELECT (23)	392 Patients with progressive RAIR-DTC	Placebo-controlled phase III	Median PFS = 18.3 months (lenvatinib) vs. 3.6 months (placebo)
MTC
Vandetanib	VEGFR1–3, RET, EGFR, BRK, TIE2, EPHR, SRC	ZETA (63)	331 Patients with RECIST measurable MTC	Placebo-controlled phase III	Median PFS = 30.5 months (est.) (vandetanib) vs. 19.3 months (placebo)
Cabozantinib	VEGFR1–3, RET, MET, KIT, TRKB, FLT-3	EXAM (65)	330 Patients with progressive MTC	Placebo-controlled phase III	Median PFS = 11.2 months (cabozantinib) vs. 4.0 months (placebo)

MTC, medullary thyroid carcinoma; PFS, progression-free survival; RAIR-DTC, radioiodine-resistant differentiated thyroid cancer; RECIST, Response Evaluation Criteria in Solid Tumors.